,Lengsin (270-279),,Leukocyte Proteinase-3 (169-177), CAS

BOC Sciences 企業の連絡先情報

名前:	BOC Sciences
電話番号:	-16314854226;
電子メール:	inquiry@bocsci.com
国籍:	United States
ウェブサイト:	https://www.bocsci.com/
商品の合計数:	19654

143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197

製品カタログ

MART-1 (24-33(34))
MART-1 (1-20)
MAGE-12 (114-127)
MAGE-2 (127-136)
Leukocyte Proteinase-3 (169-177)
MAGE-1 (278-286)
MAGE-1 (62-70)
MAGE-1 (268-282)
lymphocyte antigen 6 complex locus K (114-133)
MAGE-1 (222-231)
MAGE-1 (96-104)
MAGE-2 (157-166)
lymphocyte antigen 6 complex locus K (61-84)
MAGE-1 (289-298)
Lengsin (270-279)
MAGE-12 (170-178)
MAGE-3 (111-125)
L-Homocarnosine dihydrochloride	1807885-26-2	C10H17ClN4O3
Mammaglobin-A (23-31)
MARK Substrate	847991-34-8	C60H108N18O21
MART-1 (100-111)
Mammaglobin-A precursor (2-10)
MAPK/MAK/MRK overlapping kinase (352-360)
Mammaglobin-A precursor (83-92)
MAGE-2 (156-164)
MAGE-2 (212-220)
MAPK/MAK/MRK overlapping kinase (32-40)
Mammaglobin-A precursor (66-74)
MAGE-6 (290-298)
MAGE-3 (97-105)
MAGE-6 (293-301)
MAGE-9 (223-231)
MART-1 (100-116)
MAPK/MAK/MRK overlapping kinase (11-20)
MAGE-1 (281-292)
MAGE-4 (156-163)
MAGE-3 (168-176)
MAGE-4 (230-239)
MAGE-3 (113-121)
MAGE-3 (167-176)
MAGE-3 (161-175)
MAGE-5 (5-12)
MAGE-1 (90-104)
MAGE-3 (114-122)
MAGE-6 (168-176)
MAGE-3 (119-134)
MAGE-3 (281-295)
MAGE-4 (143-151)
MAGE-3 (191-205)
MAGE-6 (121-134)
MAGE-3 (143-151)
MAGE-3 (149-160)
MAGE-3 (111-126)
MAGE-1 (102-112)
lymphocyte antigen 6 complex locus K (119-128)
LPGAT1 (262-270)
L-lactate dehydrogenase A chain (254-265)
Mammaglobin-A precursor (32-40)
Mammaglobin-A precursor (4-12)
LXW7	1313004-77-1	C29H48N12O12S2
M-2420	310427-95-3	C70H91N15O27
MART-1 (100-114)
MAGE-3 (243-258)
MAGE-3 (112-120)
MAGE-3 (267-282)
MAGE-4 (169-177)
Melanoma-associated antigen C1 (1083-1091)
Melanoma-associated antigen C2 (42-50)
Melanoma antigen preferentially expressed in tumors (142-151)
Melanoma-associated antigen C2 (191-200)
Melanoma-associated antigen C1 (450-458)
Melanoma antigen preferentially expressed in tumors (300-309)
Melanoma-associated antigen C1 (779-787)
Melanoma-associated antigen C1 (959-968)
Melanoma-associated antigen C2 (307-315)
Melanoma-associated antigen C2 (43-57)
Melanoma antigen preferentially expressed in tumors (301-309)
Melanoma-associated antigen C2 (336-344)
Melanoma-associated antigen C1 (137-149)
Melanoma antigen preferentially expressed in tumors (425-433)
MAGE-10 (254-262)
MAGE-1 (230-238)
MAGE-12 (127-141)
MAGE-10 (290-298)
Melanoma antigen preferentially expressed in tumors (100-108)
melanoma-overexpressed antigen 1 (11-23)
MART 1 peptide (1-10)
MART-1 (51-73)
Matrix protein 1 (27-35)
MART-1 (97-116)
Melanocyte protein Pmel 17 precursor (40-57)
Melanoma antigen gp100 (280-288)
Melanocyte protein Pmel 17 precursor (46-57)
Melanocyte protein Pmel 17 precursor (45-57)
MART-1 (32-40)
MART-1 (91-110)
Melanocyte protein Pmel 17 precursor (44-57)
Matrilysin (96-107)
MART-1 (51-61)
Matrix protein 1 (229-237)